Amylx Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while Snap On Incorporated trades at $407.04 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 8.1× Amylx Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SNA | |
|---|---|---|
Market Cap | $2.64B | $21.30B |
Sector | Health | Technology |
52-Week High | $24.19 | $419.31 |
52-Week Low | $7.82 | $321.38 |
Enterprise Value | $2.39B | $20.93B |
Dividend Yield | — | 2.37% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Snap-on (SNA) trades at $407.04, down 0.99% today, with a bullish technical signal from moving averages and support near $406. The company reported strong Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% and a net income margin of 19.6%. Recent acquisitions like Diesel Laptops for $100 million aim to expand its diagnostics reach.
The outlook remains positive with a consensus price target of $455.33, implying 12% upside, supported by robust cash flow and dividend payments. Key risks include integration costs from acquisitions and premium valuation multiples, while softer OEM demand and economic sensitivity could pressure near-term performance.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →